Attached files

file filename
EX-99.1 - EXHIBIT 99.1 - ACURA PHARMACEUTICALS, INCv424179_ex99-1.htm

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D. C. 20549

 

 

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act Of 1934

 

November 10, 2015

Date of Report (Date of earliest event reported)

 

 

 

ACURA PHARMACEUTICALS, INC.

(Exact Name of Registrant as Specified in Charter)

 

 

 

State of New York 1-10113 11-0853640
(State of Other Jurisdiction
of Incorporation)
(Commission
File Number)
(I.R.S. Employer
Identification Number)

 

616 N. North Court, Suite 120

Palatine, Illinois 60067

(Address of principal executive offices) (Zip Code)

 

(847) 705-7709

(Registrant’s telephone number, including area code)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

¨   Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨   Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17CFR 240.14a-12)

¨   Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17CFR240.14d- 2(b))

¨   Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17CFR 240.13e- 4(c))

 

 

 

 

Item 8.01Other Events

 

On November 10, 2015 we issued a press release announcing receipt of the 2015 North American Opioid Oral Abuse Deterrence Technology Innovation Leadership Award from independent analyst firm Frost & Sullivan. The press release is attached hereto as Exhibit 99.1.

 

 

Item 9.01Financial Statements and Exhibits

 

Exhibit NumberDescription

 

99.1Press Release dated November 10, 2015

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

  ACURA PHARMACEUTICALS, INC.  
     
     
  By:  /s/ Peter A. Clemens  
    Peter A. Clemens
Senior Vice President & Chief Financial Officer

 

Date: November 10, 2015

 

 

 

 

Exhibit Index

 

Exhibit NumberDescription

 

99.1Press Release dated November 10, 2015